Victory Capital Management Inc. Increases Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Victory Capital Management Inc. grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 465,694 shares of the medical research company’s stock after buying an additional 5,876 shares during the quarter. Victory Capital Management Inc. owned approximately 0.90% of Charles River Laboratories International worth $96,203,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CRL. Czech National Bank raised its stake in Charles River Laboratories International by 0.5% during the 1st quarter. Czech National Bank now owns 9,025 shares of the medical research company’s stock valued at $2,445,000 after buying an additional 41 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in shares of Charles River Laboratories International by 1.0% in the second quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock worth $914,000 after acquiring an additional 45 shares during the period. Tortoise Investment Management LLC increased its position in Charles River Laboratories International by 77.0% during the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 57 shares during the last quarter. Dumont & Blake Investment Advisors LLC lifted its holdings in Charles River Laboratories International by 1.4% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company’s stock valued at $1,196,000 after acquiring an additional 62 shares during the period. Finally, Mitchell & Pahl Private Wealth LLC boosted its position in Charles River Laboratories International by 2.0% in the second quarter. Mitchell & Pahl Private Wealth LLC now owns 3,154 shares of the medical research company’s stock worth $652,000 after purchasing an additional 62 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Down 1.7 %

NYSE CRL opened at $187.96 on Friday. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The stock has a market cap of $9.68 billion, a PE ratio of 22.11, a P/E/G ratio of 3.97 and a beta of 1.36. The stock’s 50 day moving average is $210.24 and its 200 day moving average is $227.56.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 7th. The medical research company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.39 by $0.41. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. Research analysts predict that Charles River Laboratories International, Inc. will post 10.02 EPS for the current fiscal year.

Charles River Laboratories International announced that its board has approved a share repurchase program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

CRL has been the topic of several recent research reports. StockNews.com upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Tuesday, August 20th. Evercore ISI decreased their price target on shares of Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Argus reiterated a “hold” rating on shares of Charles River Laboratories International in a research note on Friday, June 28th. Robert W. Baird lowered Charles River Laboratories International from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $239.00 to $191.00 in a research note on Thursday, August 8th. Finally, Barclays cut their price target on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Ten analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $231.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).